Nanobiocomposites for Drug Delivery

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".

Deadline for manuscript submissions: closed (20 April 2023) | Viewed by 1694

Special Issue Editors


E-Mail Website
Guest Editor
Max Planck Laboratory for Structural Biology, Chemistry and Molecular Biophysics of Rosario (MPLbioR, UNR-MPIbpC), Partner Laboratory of the Max Planck Institute for Biophysical Chemistry (MPIbpC, MPG), CONICET Rosario, Maipú 1065, Rosario S2000, Argentina
Interests: nanobiomaterials; drug delivery; biomaterials; biopolymers; nanoparticles (lipid, metallic, polymeric); biocatalysis; enzyme immobilization
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Center for Natural and Human Sciences, Federal University of ABC, Santo André 09210-580, SP, Brazil
Interests: X-ray powder diffraction; crystal structure; Rietveld method; pair distribution function
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Over the last two decades, the advancement of drug delivery (DD) devices has increased exponentially because several problems associated with drug administration and toxicity were reported. Considerable improvements have been carried out for the progress of DD systems to accomplish better patient compliance with lower toxicity, improved pharmacokinetic profile, and proper targeting. Under this framework, nanocomposites, defined as multiphase material with at least one dimension less than 100 nm and/or phase components with distances at the nanoscale, showed new alternatives for the development of novel DD structures. More recently, the availability of a large number of biomolecules with high purity and the recent advances in biophysical techniques to analyze and characterize the interactions between the nanocomposites open a wide window for the development of DD nanobiocomposites (NBCs). One of main advantages of NBCs is the myriad of potential molecules that could be blended, including nanoparticles, biomolecules, and inorganic and/or organic compounds, which provide unique NBCs for any DD applications with the potential benefits of being naturally responsive to the environmental conditions and biodegradability without the release of undesirable toxic by-products. The present Special Issue will cover different approaches for the application of NBCs for drug delivery, which will involve improved drug efficacy, bioavailability, the control release of drugs and/or bioactive molecules (and their kinetic, novel, NBC-targeted delivery), and other topics of interest to develop novel NBCs for drug delivery applications.

Prof. Dr. Guillermo R. Castro
Dr. Fabio Furlan Ferreira
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • nanocomposite hydrogels
  • hybrid nanoparticles
  • 3D bioprinting
  • nanozymes
  • hybrid films
  • sol–gel process
  • amphiphilic nanostructures
  • dopped ceramics
  • drug–matrix interactions
  • nanocomposite functionalization

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

14 pages, 3440 KiB  
Article
PLLA Composites Combined with Delivery System of Bioactive Agents for Anti-Inflammation and Re-Endothelialization
by Seung-Woon Baek, Da-Seul Kim, Duck Hyun Song, Semi Lee, Jun-Kyu Lee, So-Yeon Park, Jun Hyuk Kim, Tae-Hyung Kim, Chun Gwon Park and Dong Keun Han
Pharmaceutics 2022, 14(12), 2661; https://doi.org/10.3390/pharmaceutics14122661 - 30 Nov 2022
Cited by 7 | Viewed by 1486
Abstract
The development of a biodegradable vascular scaffold (BVS) for the treatment of cardiovascular diseases (CVDs) still requires some improvement. Among them, re-endothelialization and anti-inflammation are clinically important to restore vascular function. In this study, we proposed a coating system to deliver hydrophilic bioactive [...] Read more.
The development of a biodegradable vascular scaffold (BVS) for the treatment of cardiovascular diseases (CVDs) still requires some improvement. Among them, re-endothelialization and anti-inflammation are clinically important to restore vascular function. In this study, we proposed a coating system to deliver hydrophilic bioactive agents to BVS using nanoemulsion and drop-casting methods. The poly(L-lactide) (PLLA) scaffold containing magnesium hydroxide (MH) was coated on the surface with bioactive molecules such as polydeoxyribonucleotide (PDRN), L-arginine (Arg, R), and mesenchymal stem cell-derived extracellular vesicles (EVs). PDRN upregulates the expression of VEGF as one of the A2A receptor agonists; and Arg, synthesized into nitric oxide by intracellular eNOS, induces endothelialization. In particular, EVs, which are composed of a lipid bilayer and transfer bioactive materials such as protein and nucleic acid, regulate homeostasis in blood vessels. Such a bioactive agent coating system and its PLLA composite suggest a new platform for the treatment of cardiovascular dysfunction. Full article
(This article belongs to the Special Issue Nanobiocomposites for Drug Delivery)
Show Figures

Figure 1

Back to TopTop